The Necessity of Cytoreductive Nephrectomy in Patients With Metastatic Renal Cell Carcinoma Using Antiangiogenic Targeted Therapy After Interferon Alfa-2b

This publication has 11 references indexed in Scilit:

• Improved survival in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy in the era of targeted therapy
  International Journal of Clinical Oncology, 2013
• Does Timing of Cytoreductive Nephrectomy Impact Patient Survival With Metastatic Renal Cell Carcinoma in the Tyrosine Kinase Inhibitor Era? A Multi-institutional Study
  Urology, 2013
• Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis
  World Journal of Urology, 2012
• Cytoreductive nephrectomy in metastatic renal cell carcinoma
  Current Opinion in Urology, 2008
• Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
  New England Journal of Medicine, 2007
• Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma: Is It Still Imperative in the Era of Targeted Therapy?
  Clinical Cancer Research, 2007
• Cytoreductive nephrectomy: is it a realistic option in patients with renal cancer?
  BJU International, 2002
• Renal cancer: molecular mechanisms and newer therapeutic options
  Current Opinion in Nephrology and Hypertension, 2002
• Nephrectomy Followed by Interferon Alfa-2b Compared with Interferon Alfa-2b Alone for Metastatic Renal-Cell Cancer
  New England Journal of Medicine, 2001
• Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial
  The Lancet, 2001